Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial - sprookjes - yvandenbroek - TriplyDB

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

http://www.wikidata.org/entity/Q57628798

about

Management of the cardiorenal syndrome in decompensated heart failure AKI and Long-Term Risk for Cardiovascular Events and Mortality.Effect of renal function on prognosis in chronic heart failure.Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations.Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction Worsening of renal function during 1 year after hospital discharge is a strong and independent predictor of all-cause mortality in acute decompensated heart failure Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF Prevalence and prognostic impact of kidney disease on heart failure patients.Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure Incorporating common biomarkers into the clinical management of heart failure The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.Noncardiac comorbidities and acute heart failure patients.Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.The TNF-α/sphingosine-1-phosphate signaling axis drives myogenic responsiveness in heart failure.Cardiorenal syndrome: pathophysiology and treatment.Prognostic factors in patients hospitalized for heart failure.Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?Ultrafiltration Therapy for Heart Failure: Balancing Likely Benefits against Possible Risks.Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists.Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.Progress or lack of progress in hospitalized heart failure.Hemodynamic and neurochemical determinates of renal function in chronic heart failure.Prognostic value of glomerular filtration rate estimation equations in acute heart failure with preserved versus reduced ejection fraction.Initiation and Cessation Timing of Renal Replacement Therapy in Patients with Type 1 Cardiorenal Syndrome: An Observational Study.

P2860

Q27028203-050359B1-7D08-4E48-9314-21FE92E85B46 Q30249640-3FA68A3A-186B-4227-9823-3D8A79D3B7B2 Q30361766-A41CAE61-CB30-40F8-8EDC-C10CAF81C9DD Q34244029-8D70EDDE-9AF7-49AF-93C4-6590288ECB5C Q34264037-D3BBE490-604D-49F8-B08F-EBBD793F61C3 Q34350739-0589EF17-CEB8-449B-BBC2-5C1DE863689F Q34486006-B20676E5-93D2-4723-AC2C-97121BAA8A8D Q34625223-71BC7790-BA8A-4B83-A081-6E52AEB1CADC Q35114953-221C0EC4-792F-43E3-BFBC-DC8F9167A5B2 Q35684955-F878E5CA-7137-4065-8277-3A94BEF5A80C Q36517260-839FADA0-0485-41D6-B7C5-B824E7D64B36 Q37194692-0F1975F8-5169-40F7-BB3B-934601ADC525 Q37206133-222BDBF7-B293-424D-B5AD-BF9F7E4A1FFC Q37347009-989F2DA1-F47C-4F4C-8F17-DD0DAFD73F84 Q37385135-84184731-A3EC-4977-9D44-DA4A5BB6A018 Q37425473-730F5F67-CAB4-4FE7-937E-3714AB3958A7 Q37531314-83A761FD-2948-4F5D-BEE1-BEA408E94FEF Q38009708-3A307550-DB25-41EE-A343-8B228170F122 Q38099718-74595EB5-A969-4532-951A-DDB28A5EA755 Q38108765-4F2C21B0-8B9D-42EF-B98F-48FE43734536 Q38152290-94991C0D-04C1-4681-9C7D-3D6A10BAC45C Q38383238-07CCB009-F2EB-427D-AC41-09A6571E0454 Q38478533-C641B1A5-0C74-4240-BBC3-4D9088BF37B8 Q38516856-BE7B3AC2-6085-4B60-A00B-298FD48A2C53 Q38795329-481D2AFF-DA54-4636-93CA-D8F7B84C94F9 Q39021158-BDCE7EB6-5E59-4C93-B726-EC55C9AC26BC Q40459537-46EA977B-C5A2-46DC-9F1F-3D02174282EA Q44622051-03EC2DE2-DEAB-4964-9013-D1D7DC8EE3B9 Q45904891-8A4ABB5D-76BA-4C05-8B7F-4A96E2A0E8D3 Q48105595-3DD35B56-14DD-44C4-B137-B21651C612FD Q50963368-C9D729F4-E971-474C-B210-0A404D2AFA49 Q54561734-30DE401F-E18E-4799-9D36-843CCC4D2D03

P2860

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

http://www.wikidata.org/entity/Q57628798

description

im Juli 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2011

@uk

name

Changes in renal function duri ...... ebo group of the EVEREST trial

@en

Changes in renal function duri ...... ebo group of the EVEREST trial

@nl

type

label

Changes in renal function duri ...... ebo group of the EVEREST trial

@en

Changes in renal function duri ...... ebo group of the EVEREST trial

@nl

prefLabel

Changes in renal function duri ...... ebo group of the EVEREST trial

@en

Changes in renal function duri ...... ebo group of the EVEREST trial

@nl

P1433

Q57628798-C672360E-6A49-4AFB-9466-E0603D72A6FD

P1476

Q57628798-988C1F7B-3EC6-4C77-BC72-F11210593517

P2093

Q57628798-03AB136A-9052-45D1-B35D-BCF8417B16AC

Q57628798-088828A0-F9C6-414E-9EE0-1248D1A0D502

Q57628798-0D4AAAA6-D5FC-473B-9FBA-7F061E5344F1

Q57628798-14D19800-31BA-4014-9AFD-853D61000F41

Q57628798-19214622-5189-465A-B985-E3F9B81A1814

Q57628798-3573545C-85A3-4322-A219-379306A1527B

Q57628798-552B44DF-481D-48C4-ABA1-2AE8D52D5CE9

Q57628798-6E82E9B1-813F-439B-9386-76BA32E714D7

Q57628798-9289C4F3-1DF5-4D8F-A4F6-D0BF35E3ED39

Q57628798-9DE8069C-3CCD-4C61-8CEB-4915200DC1B4

P2860

Q57628798-06AB1B90-B643-4F36-8B4F-4E54C9FE9DD4

Q57628798-096A18F0-453F-4A5A-B521-F660098CD6EA

Q57628798-167A451D-B232-4C64-93A3-0E9CE4246765

Q57628798-1F570B8F-579E-45BA-B6F1-48BB56D1E4A0

Q57628798-32F3A380-C26A-4596-8E6D-B9B3DCE48616

Q57628798-3C1E8E6B-4C76-4BE4-A74D-6E7987C91FFA

Q57628798-3D754AA2-8034-4CD0-BDBF-EB4D0F0B2EB9

Q57628798-4D6F7841-218C-42A9-8226-7850746BEE6B

Q57628798-4D89B480-46EE-4CAB-9313-61BEB78F4317

Q57628798-5077E9E6-1932-4A6F-9901-C391FC7A15CD

P304

Q57628798-3D5CE06F-955F-4BFE-8386-925AB84FE6D8

P31

Q57628798-75D53F8B-326C-4099-9651-D2EA8284DD89

P356

Q57628798-D9C4C596-2DDE-4982-A045-8ACEE62E6E3F

P433

Q57628798-3C34F525-1ED5-46EF-BE58-12360DE53A34

P478

Q57628798-584EE2C0-408B-4AE2-9B82-FD28887D70DF

P50

Q57628798-0024D94C-7A4C-44AE-8448-664E9F051CB9

Q57628798-77E2A0E2-6F38-4E96-816D-2611C968A3DC

Q57628798-928FB7E9-DDC2-4654-8A0D-84BAB0A0AB88

Q57628798-A840CB75-5364-4779-892A-C6446C1F671E

P577

Q57628798-8AF2CC3D-ECC1-453A-ADAC-13434C4B2715

P698

Q57628798-4597D758-290D-4F80-937D-15372A5B7DD8

P921

Q57628798-22F92E9C-DEB5-4CA9-BC7A-E2D27AE32E54

Q57628798-503D8139-E3D9-4ED8-BE2D-E107BC608F53

Q57628798-F689B819-2558-4856-B481-3A505609E3A8

P356

P1433

European Heart Journal

P1476

Changes in renal function duri ...... ebo group of the EVEREST trial

@en

P2093

A. Ambrosy

http://www.w3.org/2001/XMLSchema#string

A. P. Maggioni

http://www.w3.org/2001/XMLSchema#string

B. Traver

http://www.w3.org/2001/XMLSchema#string

J. C. Burnett

http://www.w3.org/2001/XMLSchema#string

J. E. A. Blair

http://www.w3.org/2001/XMLSchema#string

J. E. Udelson

http://www.w3.org/2001/XMLSchema#string

M. A. Konstam

http://www.w3.org/2001/XMLSchema#string

M. Gheorghiade

http://www.w3.org/2001/XMLSchema#string

P. S. Pang

http://www.w3.org/2001/XMLSchema#string

R. W. Schrier

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure.

Acute heart failure syndromes: current state and framework for future research.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Acute kidney injury increases risk of ESRD among elderly.

Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease.

Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward.

P304

2563-2572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHR238

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Liliana Grinfeld

P577

2011-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21785107

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization